Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Long-Term Investments (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed Long-Term Investments for 5 consecutive years, with $12.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Investments rose 28.92% to $12.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.0 million, a 28.92% increase, with the full-year FY2024 number at $9.3 million, up 19.64% from a year prior.
  • Long-Term Investments was $12.0 million for Q3 2025 at Caribou Biosciences, up from $4.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $62.5 million in Q1 2023 to a low of $4.0 million in Q1 2025.
  • A 5-year average of $16.9 million and a median of $7.8 million in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: skyrocketed 330.76% in 2023, then tumbled 87.59% in 2024.
  • Caribou Biosciences' Long-Term Investments stood at $7.6 million in 2021, then increased by 0.94% to $7.7 million in 2022, then increased by 0.71% to $7.8 million in 2023, then grew by 19.64% to $9.3 million in 2024, then grew by 28.86% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Long-Term Investments are $12.0 million (Q3 2025), $4.0 million (Q1 2025), and $9.3 million (Q4 2024).